

# Vincent Audard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/164094/publications.pdf>

Version: 2024-02-01

129  
papers

3,142  
citations

136950

32  
h-index

197818

49  
g-index

139  
all docs

139  
docs citations

139  
times ranked

3555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 531-539.	0.7	10
2	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. <i>American Journal of Kidney Diseases</i> , 2022, 79, 56-68.e1.	1.9	11
3	Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 386-396.	7.3	14
4	Thrombospondin type-1 domain-containing 7A-related membranous nephropathy associated with glomerular AL amyloidosis. <i>Pathology</i> , 2022, 54, 654-657.	0.6	2
5	B-Cell Dysregulation in Idiopathic Nephrotic Syndrome: What We Know and What We Need to Discover. <i>Frontiers in Immunology</i> , 2022, 13, 823204.	4.8	19
6	Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?. <i>Rheumatology</i> , 2022, 61, 4056-4064.	1.9	6
7	Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. <i>Kidney International</i> , 2022, 101, 416-418.	5.2	7
8	Prevalence and determinants of iron deficiency in cardiac amyloidosis. <i>ESC Heart Failure</i> , 2022, 9, 1314-1327.	3.1	4
9	Acute Kidney Injury in Critically-Ill COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2029.	2.4	6
10	<i>De novo</i> IgA vasculitis following adenovirus-based SARS-CoV-2 vaccination. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 587-589.	2.9	5
11	Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1574-1582.	2.9	7
12	Kidneyâ€œTargeted drug delivery systems based on tailor-made nanocapsules. <i>Chemical Engineering Journal</i> , 2021, 404, 126475.	12.7	7
13	Natural history and impact of treatment with tafamidis on major cardiovascular outcomeâ€œfree survival time in a cohort of patients with transthyretin amyloidosis. <i>European Journal of Heart Failure</i> , 2021, 23, 264-274.	7.1	30
14	Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 609-617.	0.7	18
15	Impact of renal function on hydroxyurea exposure in sickleâ€œcell disease patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2274-2285.	2.4	2
16	Hypermetabolic bilateral kidney enlargement associated with diffuse large B-cell lymphoma. <i>Lancet Oncology</i> , The, 2021, 22, e81.	10.7	0
17	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	4.7	8
18	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1253-1262.	0.7	54

#	ARTICLE	IF	CITATIONS
19	Continuous positive airway pressure for respiratory support during COVID-19 pandemic: a frugal approach from bench to bedside. <i>Annals of Intensive Care</i> , 2021, 11, 38.	4.6	18
20	Comparison of Plasma Clearance With Early-Compartment Correction Equations and Urinary Clearance in High GFR Ranges. <i>Kidney International Reports</i> , 2021, 6, 1622-1628.	0.8	4
21	Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits. <i>Diagnostics</i> , 2021, 11, 710.	2.6	8
22	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
23	Impact of pre-eclampsia on renal outcome in sickle cell disease patients. <i>British Journal of Haematology</i> , 2021, 194, 1053-1062.	2.5	4
24	Renal diseases secondary to interferon- $\beta$ treatment: a multicentre clinico-pathological study and systematic literature review. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2563-2572.	2.9	8
25	CMIP interacts with WT1 and targets it on the proteasome degradation pathway. <i>Clinical and Translational Medicine</i> , 2021, 11, e460.	4.0	5
26	Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. <i>Journal of Nephrology</i> , 2021, , 1.	2.0	2
27	Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys. <i>Kidney International Reports</i> , 2021, 6, 2134-2143.	0.8	4
28	Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. <i>PLoS ONE</i> , 2021, 16, e0257189.	2.5	12
29	Scleroderma renal crisis following mRNA vaccination against SARS-CoV-2. <i>Kidney International</i> , 2021, 100, 940-941.	5.2	10
30	De Novo Focal and Segmental Glomerulosclerosis After COVID-19 in a Patient With a Transplanted Kidney From a Donor With a High-risk APOL1 Variant. <i>Transplantation</i> , 2021, 105, 206-211.	1.0	12
31	History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. <i>ESC Heart Failure</i> , 2021, 8, 5501-5512.	3.1	11
32	Causes and Circumstances of Death: Analysis in 266 Sickle Cell Adult Patients. <i>Blood</i> , 2021, 138, 974-974.	1.4	2
33	Assessing Cardiac Amyloidosis Subtypes by Unsupervised Phenotype Clustering Analysis. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2177-2192.	2.8	11
34	Creatinine clearance after cimetidine administration in a new short procedure: comparison with plasma and renal clearances of iohexol. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 587-596.	2.9	7
35	CMIP is a negative regulator of T cell signaling. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1026-1041.	10.5	15
36	Tubular Acidification Defect in Adults with Sickle Cell Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 16-24.	4.5	13

#	ARTICLE	IF	CITATIONS
37	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
38	Comparison of Iohexol Plasma Clearances Calculated From 5 Early-Compartment Correction Equations With Urinary Clearance of Iohexol. <i>Kidney International Reports</i> , 2020, 5, 1842-1843.	0.8	1
39	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2647-2657.	1.6	24
40	Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 698.	2.4	5
41	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 964-972.	4.5	13
42	Spectre des atteintes rénales. , 2020, , 125-134.		0
43	Infections and Collapsing Glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2020, 76, 600-601.	1.9	0
44	Survival and specific outcome of sickle cell disease patients after renal transplantation. <i>British Journal of Haematology</i> , 2019, 187, 676-680.	2.5	15
45	Podocyte Injury in Lupus Nephritis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1340.	2.4	34
46	Myelodysplastic Syndrome in Hemodialysis Patients. <i>Kidney International Reports</i> , 2019, 4, 1175-1178.	0.8	3
47	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1206-1219.	6.1	85
48	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. <i>Kidney International Reports</i> , 2019, 4, 1354-1358.	0.8	3
49	Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 594.	2.4	17
50	Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 961-975.	3.0	5
51	Outcomes of Older Patients (>60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 298.	2.4	3
52	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. <i>Blood</i> , 2019, 133, 576-587.	1.4	78
53	Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends. <i>Blood</i> , 2019, 134, 1031-1031.	1.4	2
54	NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. <i>Journal of Autoimmunity</i> , 2018, 88, 91-102.	6.5	56

#	ARTICLE	IF	CITATIONS
55	Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. <i>Transplant International</i> , 2018, 31, 377-385.	1.6	12
56	Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis. <i>PLoS ONE</i> , 2018, 13, e0207066.	2.5	12
57	Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring. <i>Journal of Clinical Medicine</i> , 2018, 7, 430.	2.4	9
58	Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: a retrospective study of 8 cases. <i>BMC Nephrology</i> , 2018, 19, 331.	1.8	5
59	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). <i>Kidney International</i> , 2018, 94, 1217-1226.	5.2	20
60	Mott cell interstitial nephritis revealing Waldenström macroglobulinaemia. <i>Annals of Hematology</i> , 2018, 97, 1735-1736.	1.8	0
61	Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data. <i>Blood</i> , 2018, 132, 7-7.	1.4	1
62	Study of Metabolic Acidosis in Sickle Cell Disease Patients. <i>Blood</i> , 2018, 132, 3667-3667.	1.4	0
63	Nephrotic Syndrome in Small Cell Lung Cancer and Induction of C-Mip in Podocytes. <i>American Journal of Kidney Diseases</i> , 2017, 69, 477-480.	1.9	4
64	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. <i>Transplant International</i> , 2017, 30, 256-265.	1.6	30
65	AA amyloidosis is an emerging cause of nephropathy in obese patients. <i>European Journal of Internal Medicine</i> , 2017, 39, e18-e20.	2.2	11
66	Ischemic myopathy revealing systemic calciphylaxis. <i>Muscle and Nerve</i> , 2017, 56, 529-533.	2.2	5
67	C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study. <i>Transplant International</i> , 2017, 30, 277-287.	1.6	12
68	Arteriovenous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes. <i>American Journal of Hematology</i> , 2017, 92, 136-140.	4.1	18
69	Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises. <i>American Journal of Kidney Diseases</i> , 2017, 69, 51-59.	1.9	13
70	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 33, 1579-1590.	0.7	37
71	Sickle cell disease and albuminuria: recent advances in our understanding of sickle cell nephropathy. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 475-478.	2.9	19
72	Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. <i>PLoS ONE</i> , 2017, 12, e0178572.	2.5	14

#	ARTICLE	IF	CITATIONS
73	Reversible kidney iron accumulation in a patient with sickle cell disease treated with hydroxyurea. American Journal of Hematology, 2016, 91, 1283-1284.	4.1	2
74	Repression of CMIP transcription by WT1 is relevant to podocyte health. Kidney International, 2016, 90, 1298-1311.	5.2	17
75	Monotypic plasma cell interstitial nephritis as the only clinical manifestation in a patient with previously undiagnosed indolent multiple myeloma. Medicine (United States), 2016, 95, e4391.	1.0	6
76	Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non-Sickle dialysis patients. British Journal of Haematology, 2016, 174, 148-152.	2.5	32
77	Advagraf <sup>®</sup> , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transplant International, 2016, 29, 860-869.	1.6	34
78	Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1847-1853.	6.1	75
79	B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. Journal of the American Society of Nephrology: JASN, 2016, 27, 2520-2527.	6.1	75
80	The Role of c-mip in the Pathogenesis of Minimal Change Nephrotic Syndrome. , 2016, , 81-91.		0
81	Arterio-Venous Fistula Is an Applicable Vascular Access for Erythrocytapheresis in Patients with Sickle Cell Disease. Blood, 2016, 128, 4856-4856.	1.4	0
82	Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrology Dialysis Transplantation, 2015, 30, 1047-1050.	0.7	51
83	Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice. British Journal of Haematology, 2015, 170, 192-199.	2.5	17
84	Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney International, 2014, 85, 457-470.	5.2	84
85	Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders. Medicine (United States), 2014, 93, 350-358.	1.0	36
86	Immunopathogenesis of idiopathic nephrotic syndrome with relapse. Seminars in Immunopathology, 2014, 36, 421-429.	6.1	40
87	First evidence of subclinical renal tubular injury during sickle-cell crisis. Orphanet Journal of Rare Diseases, 2014, 9, 67.	2.7	22
88	APOL1 Polymorphisms and Development of CKD in an Identical-Twin Donor and Recipient Pair. American Journal of Kidney Diseases, 2014, 63, 816-819.	1.9	51
89	Causes of Death in Sickle Cell Disease Adult Patients: Old and New Trends. Blood, 2014, 124, 2715-2715.	1.4	19
90	Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet Journal of Rare Diseases, 2013, 8, 65.	2.7	32

#	ARTICLE	IF	CITATIONS
91	Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. <i>Kidney International</i> , 2013, 83, 511-516.	5.2	115
92	Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. <i>Kidney International</i> , 2013, 83, 414-425.	5.2	33
93	Acute Renal Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 392-398.	4.5	135
94	c-mip Down-Regulates NF- $\kappa$ B Activity and Promotes Apoptosis in Podocytes. <i>American Journal of Pathology</i> , 2012, 180, 2284-2292.	3.8	27
95	Upregulation of Nuclear Factor-Related Kappa B Suggests a Disorder of Transcriptional Regulation in Minimal Change Nephrotic Syndrome. <i>PLoS ONE</i> , 2012, 7, e30523.	2.5	26
96	Acute Interstitial Nephritis With Predominant Plasmacytic Infiltration in Patients With HIV-1 Infection. <i>American Journal of Kidney Diseases</i> , 2012, 59, 711-714.	1.9	7
97	Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. <i>Transplant International</i> , 2012, 25, e62-e66.	1.6	43
98	Recurrence from primary and secondary glomerulopathy after renal transplant. <i>Transplant International</i> , 2012, 25, 812-824.	1.6	42
99	Immunopathogenesis of Idiopathic Nephrotic Syndrome. <i>Contributions To Nephrology</i> , 2011, 169, 94-106.	1.1	38
100	Intrarenal IFN- $\gamma$ mRNA Expression Differentiates Clinical and Subclinical Glomerulitis in Renal Transplant Recipients. <i>Transplantation</i> , 2011, 92, 170-175.	1.0	7
101	T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1087-1093.	0.7	34
102	Face Transplantation Outcomes: Feasibility, Reproducibility and Efficacy. <i>Plastic and Reconstructive Surgery</i> , 2010, 126, 9.	1.4	0
103	Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. <i>Blood</i> , 2010, 115, 3756-3762.	1.4	59
104	Glomerular Collapse Associated With Subtotal Renal Infarction in Kidney Transplant Recipients With Multiple Renal Arteries. <i>American Journal of Kidney Diseases</i> , 2010, 55, 558-565.	1.9	22
105	Renal Transplantation in Patients with Sarcoidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2101-2108.	4.5	43
106	Immunological risk in recipients of kidney transplants from extended criteria donors. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2745-2753.	0.7	15
107	Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2524-2529.	0.7	56
108	c-mip Impairs Podocyte Proximal Signaling and Induces Heavy Proteinuria. <i>Science Signaling</i> , 2010, 3, ra39.	3.6	99

#	ARTICLE	IF	CITATIONS
109	Glomerular Lesions in Patients With Sickle Cell Disease. <i>Medicine (United States)</i> , 2010, 89, 18-27.	1.0	68
110	Comparison of 3 Estimation Methods of Mycophenolic Acid AUC based on a Limited Sampling Strategy in Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 224-232.	2.0	11
111	Renal Lesions Associated with IgM-Secreting Monoclonal Proliferations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1339-1349.	4.5	89
112	Intragraft Levels of Foxp3 mRNA Predict Progression in Renal Transplants with Borderline Change. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2277-2281.	6.1	33
113	Arteriolar Hyalinization Predicts Delayed Graft Function in Deceased Donor Renal Transplantation. <i>Transplantation</i> , 2008, 86, 1002-1005.	1.0	20
114	The Regulatory/Cytotoxic Graft-Infiltrating T Cells Differentiate Renal Allograft Borderline Change From Acute Rejection. <i>Transplantation</i> , 2007, 83, 341-346.	1.0	44
115	Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. <i>Transplant International</i> , 2007, 21, 070915194042001-???.	1.6	65
116	A 59-kd Renal Antigen as a New Target for Rapidly Progressive Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2007, 49, 710-716.	1.9	3
117	Successful Combined Heart and Kidney Transplantation in a Patient With Sickle-cell Anemia. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 993-996.	0.6	12
118	Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1053-1059.	0.7	83
119	Long-Term Benefit of Mycophenolate Mofetil in Renal Transplantation. <i>Transplantation</i> , 2005, 79, S47-S48.	1.0	14
120	Acute Graft Pyelonephritis: A Potential Cause of Acute Rejection in Renal Transplant. <i>Transplantation</i> , 2005, 80, 1128-1130.	1.0	58
121	Abnormal RNA Processing and Altered Expression of Serin-Rich Proteins in Minimal-Change Nephrotic Syndrome. <i>Pediatric Research</i> , 2005, 57, 133-137.	2.3	6
122	Idiopathic light-chain proteinuria: Case report and review of the literature. <i>American Journal of Hematology</i> , 2004, 76, 293-294.	4.1	1
123	The Filamin-A is a partner of Tc-mip, a new adapter protein involved in c-maf-dependent Th2 signaling pathway. <i>Molecular Immunology</i> , 2004, 40, 1257-1261.	2.2	20
124	Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 245-248.	0.7	85
125	Truncation of C-mip (Tc-mip), a New Proximal Signaling Protein, Induces c-maf Th2 Transcription Factor and Cytoskeleton Reorganization. <i>Journal of Experimental Medicine</i> , 2003, 198, 797-807.	8.5	72
126	Mycoplasma hominis infection in renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 495-496.	0.7	27



#	ARTICLE	IF	CITATIONS
127	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITC]. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
128	Evaluation of a new ELISA assay for monoclonal free light chain detection in patients with cardiac amyloidosis. EJHaem, 0, , .	1.0	2
129	Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0, , 1-11.	3.0	1